Milena Baptistella Grotta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Milena Baptistella Grotta has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Adyléia Aparecida Dalbo Contrera Toro
Department of Pediatric, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil
6 shared publications - Ana Paula Gaban Malheiro
Child and Adolescent Health Postgraduate Program State University of Campinas Campinas São Paulo Brazil
3 shared publications - André Moreno Morcillo
Department of Pediatrics, School of Medical Sciences State University of Campinas Campinas Sao Paulo Brazil
3 shared publications - José Dirceu Ribeiro
Department of Pediatrics, State University of Campinas, Campinas, Brazil
3 shared publications - Lívea Gianfrancesco
Child and Adolescent Health Postgraduate Program State University of Campinas Campinas São Paulo Brazil
3 shared publications - Amanda Miranda Ferreira
Department of Pediatric, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil
2 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Vol. 61 (3) , e71541
The Role of Vitamin D in Severity and Control of Asthma in Children and Adolescents: A Systematic Review and Meta-Analysis.
Vitamin D may modulate the inflammatory processes involved in asthma. To synthesize evidence on the association between serum 25-hydroxyvitamin D levels and asthma control, severity, pulmonary function, and inflammatory markers in children and adolescents. MEDLINE PubMed, BIREME, EBSCOhost, Scopus, Web of Science, EMBASE, Cochrane Library, and ProQuest until May 2025. Eligible studies enrolled participants aged 2-18 years with clinically diagnosed asthma and evaluated serum vitamin D levels in relation to asthma severity and/or control and pulmonary function parameters or type 2 inflammatory biomarkers. We included observational and randomized studies. The risk of bias for studies was assessed. Random-effects models estimated pooled outcomes. The heterogeneity was assessed using Cochran's Q and the I² statistic. Forty-one studies (7780 participants) were included; 25 contributed to meta-analyses. Children with asthma had significantly lower serum 25(OH)D levels than healthy controls (mean difference -4.89 ng/mL; 95% CI -7.38 to -2.40; p < 0.001). Severe asthma was associated with lower vitamin D compared with mild disease (-4.21 ng/mL; 95% CI -6.43 to -1.98; p = 0.0002). No significant difference was observed between controlled and uncontrolled asthma. Correlations with pulmonary function were weak and non-significant (FEV₁ r = 0.18; p = 0.08). Vitamin D showed a moderate inverse association with total IgE (r = -0.37; p = 0.02), but not with eosinophil counts or IL-10. Heterogeneity was high across analyses. Children with asthma exhibit lower serum vitamin D levels compared with healthy peers, and these levels are inversely associated with asthma severity and total IgE. No consistent associations were observed with pulmonary function or asthma control. Further research is needed to determine whether correcting vitamin D deficiency can improve clinical and immunologic outcomes in pediatric asthma.
- 1 March 2026
- Vol. 61 (3) , e71541
Open AccessThe Role of Vitamin D in Severity and Control of Asthma in Children and Adolescents: A Systematic Review and Meta-Analysis.
Vitamin D may modulate the inflammatory processes involved in asthma. To synthesize evidence on the association between serum 25-hydroxyvitamin D levels and asthma control, severity, pulmonary function, and inflammatory markers in children and adolescents. MEDLINE PubMed, BIREME, EBSCOhost, Scopus, Web of Science, EMBASE, Cochrane Library, and ProQuest until May 2025. Eligible studies enrolled participants aged 2-18 years with clinically diagnosed asthma and evaluated serum vitamin D levels in relation to asthma severity and/or control and pulmonary function parameters or type 2 inflammatory biomarkers. We included observational and randomized studies. The risk of bias for studies was assessed. Random-effects models estimated pooled outcomes. The heterogeneity was assessed using Cochran's Q and the I² statistic. Forty-one studies (7780 participants) were included; 25 contributed to meta-analyses. Children with asthma had significantly lower serum 25(OH)D levels than healthy controls (mean difference -4.89 ng/mL; 95% CI -7.38 to -2.40; p < 0.001). Severe asthma was associated with lower vitamin D compared with mild disease (-4.21 ng/mL; 95% CI -6.43 to -1.98; p = 0.0002). No significant difference was observed between controlled and uncontrolled asthma. Correlations with pulmonary function were weak and non-significant (FEV₁ r = 0.18; p = 0.08). Vitamin D showed a moderate inverse association with total IgE (r = -0.37; p = 0.02), but not with eosinophil counts or IL-10. Heterogeneity was high across analyses. Children with asthma exhibit lower serum vitamin D levels compared with healthy peers, and these levels are inversely associated with asthma severity and total IgE. No consistent associations were observed with pulmonary function or asthma control. Further research is needed to determine whether correcting vitamin D deficiency can improve clinical and immunologic outcomes in pediatric asthma.
- Open Access
- 27 February 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (3)
The Role of Vitamin D in Severity and Control of Asthma in Children and Adolescents: A Systematic Review and Meta‐Analysis
Context: Vitamin D may modulate the inflammatory processes involved in asthma. Objective: To synthesize evidence on the association between serum 25‐hydroxyvitamin D levels and asthma control, severity, pulmonary function, and inflammatory markers in children and adolescents. Data Sources: MEDLINE PubMed, BIREME, EBSCOhost, Scopus, Web of Science, EMBASE, Cochrane Library, and ProQuest until May 2025. Study Selection: Eligible studies enrolled participants aged 2–18 years with clinically diagnosed asthma and evaluated serum vitamin D levels in relation to asthma severity and/or control and pulmonary function parameters or type 2 inflammatory biomarkers. We included observational and randomized studies. Data Extraction: The risk of bias for studies was assessed. Random‐effects models estimated pooled outcomes. The heterogeneity was assessed using Cochran's Q and the I² statistic. Results: Forty‐one studies (7780 participants) were included; 25 contributed to meta‐analyses. Children with asthma had significantly lower serum 25(OH)D levels than healthy controls (mean difference −4.89 ng/mL; 95% CI −7.38 to −2.40; p < 0.001). Severe asthma was associated with lower vitamin D compared with mild disease (−4.21 ng/mL; 95% CI −6.43 to −1.98; p = 0.0002). No significant difference was observed between controlled and uncontrolled asthma. Correlations with pulmonary function were weak and non‐significant (FEV₁ r = 0.18; p = 0.08). Vitamin D showed a moderate inverse association with total IgE ( r = −0.37; p = 0.02), but not with eosinophil counts or IL‐10. Heterogeneity was high across analyses. Conclusions: Children with asthma exhibit lower serum vitamin D levels compared with healthy peers, and these levels are inversely associated with asthma severity and total IgE. No consistent associations were observed with pulmonary function or asthma control. Further research is needed to determine whether correcting vitamin D deficiency can improve clinical and immunologic outcomes in pediatric asthma.
- 27 February 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (3)
Open AccessThe Role of Vitamin D in Severity and Control of Asthma in Children and Adolescents: A Systematic Review and Meta‐Analysis
Context: Vitamin D may modulate the inflammatory processes involved in asthma. Objective: To synthesize evidence on the association between serum 25‐hydroxyvitamin D levels and asthma control, severity, pulmonary function, and inflammatory markers in children and adolescents. Data Sources: MEDLINE PubMed, BIREME, EBSCOhost, Scopus, Web of Science, EMBASE, Cochrane Library, and ProQuest until May 2025. Study Selection: Eligible studies enrolled participants aged 2–18 years with clinically diagnosed asthma and evaluated serum vitamin D levels in relation to asthma severity and/or control and pulmonary function parameters or type 2 inflammatory biomarkers. We included observational and randomized studies. Data Extraction: The risk of bias for studies was assessed. Random‐effects models estimated pooled outcomes. The heterogeneity was assessed using Cochran's Q and the I² statistic. Results: Forty‐one studies (7780 participants) were included; 25 contributed to meta‐analyses. Children with asthma had significantly lower serum 25(OH)D levels than healthy controls (mean difference −4.89 ng/mL; 95% CI −7.38 to −2.40; p < 0.001). Severe asthma was associated with lower vitamin D compared with mild disease (−4.21 ng/mL; 95% CI −6.43 to −1.98; p = 0.0002). No significant difference was observed between controlled and uncontrolled asthma. Correlations with pulmonary function were weak and non‐significant (FEV₁ r = 0.18; p = 0.08). Vitamin D showed a moderate inverse association with total IgE ( r = −0.37; p = 0.02), but not with eosinophil counts or IL‐10. Heterogeneity was high across analyses. Conclusions: Children with asthma exhibit lower serum vitamin D levels compared with healthy peers, and these levels are inversely associated with asthma severity and total IgE. No consistent associations were observed with pulmonary function or asthma control. Further research is needed to determine whether correcting vitamin D deficiency can improve clinical and immunologic outcomes in pediatric asthma.
- Open Access
- 29 October 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (10) , e71361
Phenotype Overlap and Lung Function in Childhood Asthma: The Interaction Between T2 and Non‐T2 Responses
Purpose: This study aimed to investigate the association between asthma severity, lung function and serum levels of cytokines associated with T‐helper type 2 (T2) and non‐T2 responses in children and adolescents. Methods: We conducted a cross‐sectional study and recruited children and adolescents (7–17 years old) with asthma. Asthma severity was classified by daily corticosteroid dosage and pulmonary function, while asthma control was assessed using the Asthma Control Test and the Child Asthma Control Test. Spirometry, blood collection for cytokine analysis (IL‐4, IL‐5, IL‐10, IL‐13, IL‐17, IFNγ, TNF‐α), and induced sputum collection for cellularity evaluation were performed. Results: A total of 80 participants were included, with a mean age of 11.9 years, and 60% were male. Severe asthma was observed in 17.5%, and 15% had uncontrolled asthma. No differences in sputum cellularity were found ( p = 0.509). Cytokine levels of TNF‐α ( p = 0.043) and IL‐5 ( p = 0.010) differed by asthma severity. Negative correlations were observed between cytokines (IL‐4, IL‐5, IL‐10, IL‐17) and spirometric parameters. IL‐17 ( p = 0.001) and IL‐5 ( p = 0.045) levels varied with airway obstruction, and IL‐17 levels differed with bronchodilator response in FEV1 ( p = 0.041). Conclusions: Our findings highlight the heterogeneity of immune responses in childhood asthma. Cytokines from both T2 and non‐T2 pathways were associated with lung function impairment, underscoring the interplay of diverse immune responses in the complexity of asthma pathophysiology.
- 29 October 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (10) , e71361
Open AccessPhenotype Overlap and Lung Function in Childhood Asthma: The Interaction Between T2 and Non‐T2 Responses
Purpose: This study aimed to investigate the association between asthma severity, lung function and serum levels of cytokines associated with T‐helper type 2 (T2) and non‐T2 responses in children and adolescents. Methods: We conducted a cross‐sectional study and recruited children and adolescents (7–17 years old) with asthma. Asthma severity was classified by daily corticosteroid dosage and pulmonary function, while asthma control was assessed using the Asthma Control Test and the Child Asthma Control Test. Spirometry, blood collection for cytokine analysis (IL‐4, IL‐5, IL‐10, IL‐13, IL‐17, IFNγ, TNF‐α), and induced sputum collection for cellularity evaluation were performed. Results: A total of 80 participants were included, with a mean age of 11.9 years, and 60% were male. Severe asthma was observed in 17.5%, and 15% had uncontrolled asthma. No differences in sputum cellularity were found ( p = 0.509). Cytokine levels of TNF‐α ( p = 0.043) and IL‐5 ( p = 0.010) differed by asthma severity. Negative correlations were observed between cytokines (IL‐4, IL‐5, IL‐10, IL‐17) and spirometric parameters. IL‐17 ( p = 0.001) and IL‐5 ( p = 0.045) levels varied with airway obstruction, and IL‐17 levels differed with bronchodilator response in FEV1 ( p = 0.041). Conclusions: Our findings highlight the heterogeneity of immune responses in childhood asthma. Cytokines from both T2 and non‐T2 pathways were associated with lung function impairment, underscoring the interplay of diverse immune responses in the complexity of asthma pathophysiology.
- Open Access
- 22 August 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (8) , e71242
Is Palivizumabe a Protective Factor for the Development of Asthma in Children? A Systematic Review With Metanalysis
Introduction: Premature infants are at increased risk of developing chronic respiratory diseases, predisposing them to severe infections, such as those caused by respiratory syncytial virus (RSV). Palivizumab reduces the severity of RSV infections in high‐risk children; however, its relationship with asthma development in premature infants remains unclear. Objective: This systematic review with meta‐analysis aimed to review the literature and assess whether prophylaxis with palivizumab protects premature infants without congenital heart disease from developing asthma. Results: In total, 14 studies met the inclusion criteria, assessing 1,364,238 children; of these, 9232 received palivizumab. No significant difference in the chance of developing asthma between the groups (odds ratio (OR) of 0.84, 95% CI [0.62–1.13], p = 0.1968). Heterogeneity between studies was I ² = 35.6%. Subgroup analysis for children with a family history of atopy showed no significant reduction in asthma risk (OR 0.78, 95% CI: 0.40–1.55, p = 0.3390). Sensitivity analysis confirmed result robustness. IgE levels were similar between the groups (standardized mean difference [SMD] −0.03 [95% CI: −0.30; 0.23], p = 0.8088). Children who received palivizumab were diagnosed younger (SMD −0.24 [95% CI: −0.38; −0.09], p = 0.0014), with lower gestational age (MD −0.75 [95% CI: −1.61; 0.12], p = 0.0915). Conclusions: Palivizumab prophylaxis does not reduce asthma risk in premature children without congenital heart disease. Its primary benefit lies in preventing severe RSV infections, with no direct impact on asthma developing.
- 22 August 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (8) , e71242
Open AccessIs Palivizumabe a Protective Factor for the Development of Asthma in Children? A Systematic Review With Metanalysis
Introduction: Premature infants are at increased risk of developing chronic respiratory diseases, predisposing them to severe infections, such as those caused by respiratory syncytial virus (RSV). Palivizumab reduces the severity of RSV infections in high‐risk children; however, its relationship with asthma development in premature infants remains unclear. Objective: This systematic review with meta‐analysis aimed to review the literature and assess whether prophylaxis with palivizumab protects premature infants without congenital heart disease from developing asthma. Results: In total, 14 studies met the inclusion criteria, assessing 1,364,238 children; of these, 9232 received palivizumab. No significant difference in the chance of developing asthma between the groups (odds ratio (OR) of 0.84, 95% CI [0.62–1.13], p = 0.1968). Heterogeneity between studies was I ² = 35.6%. Subgroup analysis for children with a family history of atopy showed no significant reduction in asthma risk (OR 0.78, 95% CI: 0.40–1.55, p = 0.3390). Sensitivity analysis confirmed result robustness. IgE levels were similar between the groups (standardized mean difference [SMD] −0.03 [95% CI: −0.30; 0.23], p = 0.8088). Children who received palivizumab were diagnosed younger (SMD −0.24 [95% CI: −0.38; −0.09], p = 0.0014), with lower gestational age (MD −0.75 [95% CI: −1.61; 0.12], p = 0.0915). Conclusions: Palivizumab prophylaxis does not reduce asthma risk in premature children without congenital heart disease. Its primary benefit lies in preventing severe RSV infections, with no direct impact on asthma developing.
- 21 February 2023
- Published by Springer Nature in Lung
- Vol. 201 (2) , 181-187
Association between serum Vitamin D levels and asthma severity and control in children and adolescents
Objective To assess the association of serum Vitamin D (vitD) levels with asthma control and severity in children and adolescents in different seasons of the year. Method Longitudinal, prospective study with 7- to 17-year-old children and adolescents diagnosed with asthma. All participants underwent two assessments conducted in opposite seasons of the year which included a clinical assessment, a questionnaire for classification of asthma control (Asthma Control Test), spirometry, and blood collection to measure serum vitD levels. Results In total, 141 individuals with asthma were evaluated. The mean vitD was lower in females (p = 0.006) and sunlight exposure appears not to be an influencing factor for vitD levels. We found no differences in mean vitD of patients with controlled and uncontrolled asthma (p = 0.703; p = 0.956). However, the severe asthma group had lower mean Vitamin D than the mild/moderate asthma group for both assessments (p = 0.013; p = 0.032). In the first assessment, the group with vitD insufficiency had a higher prevalence of severe asthma (p = 0.015). Vitamin D was positively correlated with FEV1 in both assessments (p = 0.008; p = 0.006) and with FEF25–75% in the first assessment (p = 0.038). Conclusion In a tropical climate zone, there is no evidence of association between seasonality and serum vitD levels or between serum vitD levels and asthma control in children and adolescents. However, vitD and lung function were positively correlated and the group with vitD insufficiency had a higher prevalence of severe asthma.
- 21 February 2023
- Published by Springer Nature in Lung
- Vol. 201 (2) , 181-187
Association between serum Vitamin D levels and asthma severity and control in children and adolescents
Objective To assess the association of serum Vitamin D (vitD) levels with asthma control and severity in children and adolescents in different seasons of the year. Method Longitudinal, prospective study with 7- to 17-year-old children and adolescents diagnosed with asthma. All participants underwent two assessments conducted in opposite seasons of the year which included a clinical assessment, a questionnaire for classification of asthma control (Asthma Control Test), spirometry, and blood collection to measure serum vitD levels. Results In total, 141 individuals with asthma were evaluated. The mean vitD was lower in females (p = 0.006) and sunlight exposure appears not to be an influencing factor for vitD levels. We found no differences in mean vitD of patients with controlled and uncontrolled asthma (p = 0.703; p = 0.956). However, the severe asthma group had lower mean Vitamin D than the mild/moderate asthma group for both assessments (p = 0.013; p = 0.032). In the first assessment, the group with vitD insufficiency had a higher prevalence of severe asthma (p = 0.015). Vitamin D was positively correlated with FEV1 in both assessments (p = 0.008; p = 0.006) and with FEF25–75% in the first assessment (p = 0.038). Conclusion In a tropical climate zone, there is no evidence of association between seasonality and serum vitD levels or between serum vitD levels and asthma control in children and adolescents. However, vitD and lung function were positively correlated and the group with vitD insufficiency had a higher prevalence of severe asthma.
- Open Access
- 7 June 2020
- Published by Elsevier in Jornal de Pediatria
- Vol. 97 (3) , 295-301
Are there differences in the physical activity level and functional capacity among children and adolescents with and without asthma?
- 7 June 2020
- Published by Elsevier in Jornal de Pediatria
- Vol. 97 (3) , 295-301
Open AccessAre there differences in the physical activity level and functional capacity among children and adolescents with and without asthma?